Acute Pancreatitis Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approval, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight
"Acute Pancreatitis Market"
Acute Pancreatitis companies include Boston Scientific Corporation, AnGes, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd., Abbott, among several others.
(Albany, USA) DelveInsight's ' Acute Pancreatitis Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of Acute Pancreatitis, historical and forecasted epidemiology as well as the Acute Pancreatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Acute Pancreatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acute Pancreatitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Acute Pancreatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acute Pancreatitis market.
Some facts of the Acute Pancreatitis Market Report are:
The Acute Pancreatitis therapeutic market size in the 7MM was approximately USD 722 million in 2023.
In 2023, the Acute Pancreatitis market size was highest in the US among the 7MM, accounting for approximately USD 510 million which is further expected to increase by 2034 at a CAGR of 6.9%.
Leading Acute Pancreatitis companies working in the market are Boston Scientific Corporation, AnGes, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd., Abbott, and many others.
Key Acute Pancreatitis Therapies expected to launch in the market are CM-4620-IE, Evinacumab, SCM-AGH, and many others.
The estimates suggest that the gender based incidence varied in the 7MM with the male incident cases higher in the United Kingdom, Japan, and Germany, whereas in the United States the female incident cases were higher.
In approximately 15% of cases, patient can develop severe pancreatitis with tissue damage (also called Acute Necrotizing Pancreatitis (ANP)).
As per a study by Vege et al., the reported annual incidence of acute pancreatitis in the United States ranges from 4.9 to 35 per 100,000 population.
According to a study published by Ouyang et al., 2017, the incidence of acute pancreatitis ranges from 13 to 45 per 100,000 population-years and that of chronic pancreatitis ranges from 5 to 12 per 100,000 population-years.
Auxora is currently being evaluated in a Phase IIb trial for Acute Pancreatitis with accompanying SIRS, results of which are expected in first half of 2023; and in Phase I/II trial for Acute Pancreatitis in pediatric patients on asparaginase for acute lymphoblastic leukemia, results of which are expected in second half of 2022
CalciMedica: On November 13, 2024, CalciMedica announced positive data from the Phase 2b CARPO trial of Auxora (CRAC channel inhibitor) in patients with acute pancreatitis (AP). The trial showed a significant reduction in new-onset severe respiratory failure and persistent respiratory failure1. The company plans to initiate a Phase 3 program in 2025.
LipimetiX Development Inc: LipimetiX Development Inc is actively working on LipimetiX, a potential treatment for acute pancreatitis, with updates reported as of April 2024.
AcelRx Pharmaceuticals Inc: AcelRx Pharmaceuticals is developing AB-206, a drug for acute pancreatitis, with clinical trials ongoing as of April 2024.
Angion Biomedica Corp: Angion Biomedica Corp is working on Angion, a potential treatment for acute pancreatitis, with clinical trials ongoing as of April 2024.
Acute Pancreatitis Overview
Acute pancreatitis is a sudden inflammation of the pancreas, a gland located behind the stomach that plays a crucial role in digestion and blood sugar regulation. The condition can range from mild discomfort to a severe, life-threatening illness. It occurs when digestive enzymes become activated while still in the pancreas, causing the gland to begin digesting itself.
Common causes of acute pancreatitis include gallstones, which can block the pancreatic duct, and excessive alcohol consumption. Other causes may include certain medications, high triglyceride levels, abdominal trauma, infections, and genetic factors.
Symptoms typically include severe abdominal pain that radiates to the back, nausea, vomiting, fever, rapid pulse, and abdominal tenderness. Diagnosis is based on clinical presentation, blood tests showing elevated pancreatic enzymes (amylase and lipase), and imaging studies such as ultrasound, CT scans, or MRIs to assess inflammation and complications.
Treatment for acute pancreatitis usually requires hospitalization. Initial management focuses on fasting to rest the pancreas, intravenous fluids to maintain hydration, pain control, and treating the underlying cause. In severe cases, complications such as infections, cysts, or organ failure may necessitate more intensive treatments, including surgery or endoscopic procedures.
Most individuals recover fully with appropriate treatment, but severe cases can lead to chronic pancreatitis or other serious health issues, underscoring the importance of early diagnosis and intervention.
Do you know what will be the Acute Pancreatitis market share in 7MM by 2034 @ https://www.delveinsight.com/sample-request/acute-pancreatitis-market
Acute Pancreatitis Market
The Acute Pancreatitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute Pancreatitis market trends by analyzing the impact of current Acute Pancreatitis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Acute Pancreatitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acute Pancreatitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Acute Pancreatitis market in 7MM is expected to witness a major change in the study period 2020-2034.
Acute Pancreatitis Epidemiology
The Acute Pancreatitis epidemiology section provides insights into the historical and current Acute Pancreatitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acute Pancreatitis market report also provides the diagnosed patient pool, trends, and assumptions.
Interested to know how the emerging diagnostic approaches will be contributing in increased Acute Pancreatitis diagnosed prevalence pool? Download report @ Acute Pancreatitis Market Dynamics
Acute Pancreatitis Drugs Uptake
This section focuses on the uptake rate of the potential Acute Pancreatitis drugs recently launched in the Acute Pancreatitis market or expected to be launched in 2020-2034. The analysis covers the Acute Pancreatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Acute Pancreatitis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acute Pancreatitis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute Pancreatitis Pipeline Development Activities
The Acute Pancreatitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acute Pancreatitis key players involved in developing targeted therapeutics.
Download report to know which TOP 3 therapies will be capturing the largest Acute Pancreatitis market share by 2034? Click here @ Acute Pancreatitis Clinical Trials and Updates
Acute Pancreatitis Therapeutics Assessment
Major key companies are working proactively in the Acute Pancreatitis Therapeutics market to develop novel therapies which will drive the Acute Pancreatitis treatment markets in the upcoming years are Boston Scientific Corporation, AnGes, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd., Abbott, and many others.
Do you know how new drug market launch will be impacting the Acute Pancreatitis market CAGR? Download sample report @ Acute Pancreatitis therapies and drugs
Acute Pancreatitis Report Key Insights
1. Acute Pancreatitis Patient Population
2. Acute Pancreatitis Market Size and Trends
3. Key Cross Competition in the Acute Pancreatitis Market
4. Acute Pancreatitis Market Dynamics (Key Drivers and Barriers)
5. Acute Pancreatitis Market Opportunities
6. Acute Pancreatitis Therapeutic Approaches
7. Acute Pancreatitis Pipeline Analysis
8. Acute Pancreatitis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Acute Pancreatitis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Acute Pancreatitis Competitive Intelligence Analysis
4. Acute Pancreatitis Market Overview at a Glance
5. Acute Pancreatitis Disease Background and Overview
6. Acute Pancreatitis Patient Journey
7. Acute Pancreatitis Epidemiology and Patient Population
8. Acute Pancreatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Pancreatitis Unmet Needs
10. Key Endpoints of Acute Pancreatitis Treatment
11. Acute Pancreatitis Marketed Products
12. Acute Pancreatitis Emerging Therapies
13. Acute Pancreatitis Seven Major Market Analysis
14. Attribute Analysis
15. Acute Pancreatitis Market Outlook (7 major markets)
16. Acute Pancreatitis Access and Reimbursement Overview
17. KOL Views on the Acute Pancreatitis Market
18. Acute Pancreatitis Market Drivers
19. Acute Pancreatitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
2 days ago
- Japan Forward
Japan's Oldest Pharma Firm to Be Sold to Bain Capital
Mitsubishi Tanabe Pharma, Japan's oldest pharmaceutical company with a 350-year history, is approaching a major turning point. Its parent company, Mitsubishi Chemical Group, has announced plans to sell the firm to American investment fund Bain Capital. The deal is expected to be finalized between July and September 2025. This will be the first time the company, shaped by a series of corporate mergers, comes under foreign ownership. The decision reflects broader structural changes in the pharmaceutical industry. "We were like a close-knit family, living under the same roof for many years," said Manabu Chikumoto, President of Mitsubishi Chemical Group. "Mitsubishi Tanabe was a dutiful child, and I'm deeply grateful." Tsukimoto expressed regret about parting with the company, which has remained profitable and consistently delivered strong results. At the same time, he noted that the synergy between chemicals and pharmaceuticals had faded. He explained that the decision was based on the belief that Mitsubishi Tanabe's growth would be better supported under Bain Capital, which has a strong track record in healthcare investments. Mitsubishi Tanabe traces its origins back to 1678, during the Edo period, when its founder, Gohei Tanabeya I, opened a medicine shop in Tosabori, Osaka. The company began importing medicines in the early Meiji era. During the Taisho period, it built a modern pharmaceutical factory to strengthen domestic production. The company was incorporated in 1933 and later became known as Tanabe Seiyaku. Alongside Takeda Pharmaceutical and Shionogi, it earned a reputation as one of the "Three Greats of Doshomachi," a historic pharmaceutical district in Osaka. In 2007, Tanabe Seiyaku merged with Mitsubishi Pharma, which had roots in Yoshitomi Pharma and Green Cross. The merger formed what is now Mitsubishi Tanabe Pharma. In 2020, it became a wholly owned subsidiary of Mitsubishi Chemical Group, then known as Mitsubishi Chemical Holdings. A lantern of Tanabeya medicine shop, hung under the eaves from the Edo period to the early Showa era. It is currently displayed at the Mitsubishi Tanabe Pharma Museum in Chuo Ward, Osaka City. Mitsubishi Tanabe has long demonstrated strength in drug discovery. Notable products include IMUSERA for multiple sclerosis, CANAGLU for diabetes, and RADICAVA for ALS (amyotrophic lateral sclerosis) in North America. For the fiscal year ending March 2025, Mitsubishi Chemical Group's pharmaceutical segment (essentially Mitsubishi Tanabe) posted an operating profit of ¥65.4 billion JPY (around $455 million USD). This made a significant contribution to the group's overall earnings and reflected steady profitability. However, the patent for RADICAVA, the company's main revenue driver, is set to expire in North America in 2029. This is expected to trigger a "patent cliff," leading to a sharp decline in revenue. The need to develop new flagship drugs is becoming increasingly urgent. The outlook remains uncertain, especially after the United States postponed its approval of a potential Parkinson's treatment. "In-house drug development is the heart of a pharmaceutical company, but Mitsubishi Tanabe's pipeline doesn't look particularly strong," said Katsuhiko Ito, an analyst with prior experience at Yoshitomi Pharma. He pointed to the challenges of operating a pharmaceutical business within a chemical conglomerate. "Drug R&D demands long-term commitment and massive investment. That's something executives from a chemical background may struggle to fully embrace. The so-called 'diminishing synergy' between chemicals and pharmaceuticals was likely just lip service." Mitsubishi Tanabe is not alone. Other Japanese pharmaceutical companies, such as Sumitomo Pharma under Sumitomo Chemical, are also grappling with similar structural issues. The entire industry is going through a significant transformation. Once considered a drug discovery powerhouse, with multiple blockbuster drugs generating over $1 billion in annual sales, Japan's pharmaceutical sector is now losing ground. The domestic market is shrinking, and biopharmaceuticals are reshaping the global landscape. "Most drug categories have already been tapped out. What's left are the tough ones," said one industry insider. "It's a complete red ocean now." The key question is whether Mitsubishi Tanabe can revitalize its drug discovery efforts under new ownership. Mitsubishi Chemical is optimistic, citing Bain Capital's strong record in healthcare investments. The group expects Bain to inject capital into new drug development and provide strategic support for global expansion. Bain has expressed interest in exploring new growth opportunities by improving R&D productivity, commercialization, and pursuing strategic acquisitions. It has even hinted at a potential future IPO. Still, concerns remain. Critics warn that the deal could follow the typical private equity model — boosting the company's valuation in the short term, then selling off shares for profit. Shigeru Mishima, president of Pharma Asset Research, cautioned that PE owners sometimes slash R&D budgets to squeeze profits from existing products. "They treat the company like a disposable asset," he said. "That may not be the case this time, but for companies with weak development pipelines, the future could be grim." With soaring R&D costs and a declining domestic market, Japanese pharmaceutical firms are being pushed to pursue global strategies. Fumiyoshi Sakai, a UBS Securities analyst specializing in pharmaceuticals, noted this trend. He added that as major drugmakers struggle to rebuild or strengthen their domestic operations, Bain's approach will be closely watched across the industry. Whether Mitsubishi Tanabe can regain its edge in drug development and become globally competitive under Bain Capital will be a key test. This will be important not only for the company, but also for the future of Japan's pharmaceutical sector. ( Read the article in Japanese . ) Author: Sarasa Shimizu, The Sankei Shimbun
Globe and Mail
2 days ago
- Globe and Mail
Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
DelveInsight's, ' Diffuse Large B-Cell Lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL. DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment. The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies Diffuse Large B-Cell Lymphoma Emerging Drugs Profile Brentuximab vedotin: Pfizer Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. THOR-707: Sanofi THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. Abexinostat: Xynomic Pharmaceuticals Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma. RNK05047: Ranok Therapeutics RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints. BMF-219: Biomea Fusion BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. ADI-001: Adicet Bio ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. The Diffuse Large B-Cell Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment. Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market. Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs Diffuse Large B-Cell Lymphoma Companies Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report Coverage- Global Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Diffuse Large B-Cell Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Brentuximab vedotin: Pfizer Drug profiles in the detailed report….. Mid Stage Products (Phase II) THOR-707: Sanofi Drug profiles in the detailed report….. Early Stage Products (Phase I) ADI-001: Adicet Bio Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diffuse Large B-Cell Lymphoma Key Companies Diffuse Large B-Cell Lymphoma Key Products Diffuse Large B-Cell Lymphoma- Unmet Needs Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion Diffuse Large B-Cell Lymphoma Analyst Views Diffuse Large B-Cell Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Cision Canada
3 days ago
- Cision Canada
OCI Global Receives U.S. Regulatory Approval for the Sale of its Global Methanol Business to Methanex Corporation
AMSTERDAM, June 12, 2025 /CNW/ -- OCI Global (Euronext: OCI), ("OCI", the "Company") today announced that the regulatory review period under the U.S. Hart-Scott-Rodino Antitrust Act has concluded with respect to the sale of 100% of its equity interests in its Global Methanol Business ("OCI Methanol") to Methanex Corporation (TSX: MX) (Nasdaq: MEOH) ("Methanex"), (the "Transaction"). All regulatory approvals required for the closing of the Transaction have now been obtained and the Transaction is expected to close on 27 June 2025 subject to customary closing conditions. Transaction details Under the proposed Transaction, Methanex will acquire 100% of the equity interests in OCI Methanol, comprising 100% of OCI's US and European methanol assets. The Transaction consideration will be paid through a combination of approximately USD 1.2 billion of cash (taking into account net indebtedness) subject to customary closing adjustments, and the issuance of 9.9 million common shares of Methanex. 2033 Notes Tender offer As previously announced, OCI is required to launch a tender offer for its U.S.$ 600,000,000 6.700 per cent Notes due 2033 (the "Bonds") within five business days of the successful closing of the Transaction. The tender offer will be on customary terms and offer a price of 110.75% of par, plus accrued and unpaid interest. This press release contains or may contain inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. About OCI Global Learn more about OCI at You can also follow OCI on LinkedIn. About OCI Methanol OCI Methanol is a leading methanol producer in the US and through OCI HyFuels, a leading producer and distributor of green methanol today. OCI Methanol's total productive capacity comprises the following assets: A methanol facility in Beaumont, Texas with an annual production capacity of 910,000 tonnes of methanol and 340,000 tonnes of ammonia. This plant was restarted in 2011 and since that time the plant has been upgraded with USD 800 million of capital for full site refurbishment and debottlenecking. A 50 percent interest in a second methanol facility also in Beaumont, Texas, operated by Natgasoline, which is a joint venture with Proman. The Natgasoline plant was commissioned in 2018 and has an annual capacity of 1.7 million tonnes of methanol, of which Methanex's share will be 850,000 tonnes. OCI's HyFuels business, which produces and sells industry-leading volumes of low-carbon methanol and has trading and distribution capabilities for renewable natural gas (RNG). A methanol facility in Delfzijl, Netherlands with an annual capacity to produce one million tonnes of methanol. This facility is not currently in production due to unfavorable pricing for natural gas feedstock. OCI Methanol's assets are in highly strategic and developed market locations across the United States and Europe with extensive distribution and storage capabilities near major industrial demand centres and key bunkering hubs. The assets in the United States have access to stable and low-cost USGC natural gas, enabling first quartile cost curve positions. OCI HyFuels is a pioneering first-mover in providing the road, marine, power, and industrial sectors with renewable and low-carbon fuel alternatives to meet evolving regulatory requirements. The business includes the production and distribution of green methanol, bio-MTBE, renewable natural gas, and ethanol. Methanol and ammonia are key enablers of the hydrogen economy and the most logical hydrogen fuels, key to decarbonizing hard to abate industries including marine. About Methanex Methanex is a Vancouver-based, publicly traded company and is the world's largest producer and supplier of methanol globally. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol "MX" and on the Nasdaq Stock Market in the United States under the trading symbol "MEOH." Methanex can be visited online at
